Japan has approved the domestic manufacture and sale of the MMR vaccine "Mimrit," targeting children aged one and older [1], [2].
The approval marks the return of a combined measles, mumps, and rubella vaccine to the Japanese market after approximately 30 years [1]. This shift aims to streamline the immunization process for young children by consolidating three separate vaccinations into a single injection.
The Ministry of Health, Labour and Welfare granted the approval on March 2, 2026 [3], [4]. The pharmaceutical company Daiichi Sankyo developed the vaccine, which is designed to prevent the three viral infections [2], [4].
Japan previously utilized an MMR vaccine until 1993, when its use was discontinued [1]. The decision to stop the previous version was driven by concerns over the frequency of aseptic meningitis in recipients [1].
Officials said the new Mimrit vaccine has a significantly lower incidence of aseptic meningitis compared to the 1993 version [1]. This improved safety profile allowed the government's expert panel to clear the product for domestic use [2].
"Domestic MMR vaccines will be used for the first time in about 30 years," FNN said [1].
The approval followed a meeting of the second division of the Pharmaceutical Affairs Council, where the ministry finalized the authorization for Daiichi Sankyo to begin production and distribution [3].
“Domestic MMR vaccines will be used for the first time in about 30 years”
The reintroduction of the MMR vaccine reflects a critical update to Japan's public health strategy. By addressing the safety flaws that led to the 1993 suspension, the government is reducing the burden of multiple clinic visits for parents and children while strengthening herd immunity against three contagious diseases simultaneously.
